News | August 06, 2025
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Revenue increased 11.4 per cent to Rs. 8,545 crore
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Akums invested Rs. 272 crore in capital expenditure during FY25
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
